Infectious disease is not merely a problem of the past; despite significant breakthroughs achieved during the last century in the development of antibiotic, antiviral, and antiparasitic drugs and vaccines, the eradication or [...]]]> Innovations in Combating Infectious Diseases: Opportunities in therapeutics and diagnostics through application of proteomics, genomics, nanotechnology, and novel sources of lead generation
 

Infectious disease is not merely a problem of the past; despite significant breakthroughs achieved during the last century in the development of antibiotic, antiviral, and antiparasitic drugs and vaccines, the eradication or even control of many infectious diseases has not been accomplished. Of particular current concern are the problems of rapidly developing drug resistance, emerging disease, re-emerging disease, the threat of bioterrorism, and the speed of reaction to the appearance of virulent strains posing pandemic threats.

Furthermore, the effective treatment of infectious diseases is dependent on accurate and rapid diagnosis, and this in itself can present significant challenges, especially in cases where the disease progression is poorly understood or has long asymptomatic latency (such as prion diseases).

Successful drugs and vaccines against infectious agents that put millions of people at risk have potentially lucrative markets. The key to developing those drugs is to understand the pathogenic process and gain insight into where and how it can best be interrupted. This report makes a detailed and comprehensive analysis of the cutting edge of research aiming to reveal how bacteria, viruses, fungi, and prions infect and affect their hosts. It also assesses the new technologies and techniques that are being used to design and develop the anti-infective drugs and diagnostic methods of the 21st century.

Key features of this report

This report presents a snapshot of how new technologies and approaches are being applied to the discovery of new drug targets, vaccine candidates, lead compounds, and novel delivery systems that will enhance diagnostics and therapeutics across the whole range of infectious diseases:
• How proteomics is being used to identify biomarkers for new diagnostics in infectious diseases
• How proteomics is being used to identify novel targets for drug discovery and vaccine development in infectious diseases
• The impact of genomics on the search for novel targets for infectious disease drug discovery
• Novel natural sources for lead generation in infectious diseases
• Lead optimization techniques relevant to infectious diseases
• How the application of nanobiotechnology is impacting on drug discovery and drug delivery in infectious diseases

Scope of this report

• Gain awareness of the most significant areas of unmet need for anti-infective drug development.
• Build knowledge of the most promising diagnostics research – ripe for commercialization – for MRSA and community-acquired infections, bacterial meningitis, periodontal disease, and innovative ways for predicting outcome in hepatitis infections.
• Discover how proteomics and genomics are making an increasing impact on drug development programs, and how important infectious agents can be tackled by drug and vaccine approaches.
• Identify the new opportunities for small and large biotechnology based companies to undertake vaccine development based on proteomic and genomic studies

Key Market Issues

• More accurate and rapid diagnostics will remain a pressing need combating prion diseases, sexually transmitted diseases, HIV, hospital-acquired infections and bioterrorism threats.
• Diagnostics is a big area that is ripe for more commercial development, particularly for diagnostic kits that are fast and simple to operates by unskilled personnel, making them amenable to the point-of-care use.
• Personalized medicine will remain a priority; drug treatments need to be more tailored and efficient with fewer side effects, less frequent dosing, and faster action..
• Using genomics to monitor and carry out surveillance of infectious disease will become more important and more necessary, so that new outbreaks, spread of disease, and danger of pandemics can be better monitored and predicted by global warning systems.
• The need to identify, monitor, and respond to bioterrorism will continue to drive research into lethal viral infections such as small pox and ebola, and bacterial diseases such as anthrax and plague.

Key findings from this report

• Drug development, vaccine development, and novel approaches to therapeutics are needed urgently for bacterial, viral, fungal, and prion diseases, which cause high morbidity and mortality in both the developing and the developed world.
• To date, there has been an intensive research effort to use proteomics to detect, identify, characterize, and validate biomarkers and protein signatures in diagnostics for many different infectious diseases but validation and commercialization has so far proved relatively elusive.
• Drug resistance, emerging infections and the threat of bioterrorism make the understanding of virulence factors and disease pathogenesis essential to form a springboard from which to launch drug discovery programs.
• Genomics is being applied to drug discovery across the spectrum of infectious diseases, whether they are caused by bacteria, viruses, fungi, parasites, or prions. Genomic data can be used in public health surveillance and monitoring of infectious diseases, particularly when there is a threat of a pandemic or bioterrorist attack.
• Novel sources of lead compounds to screen against newly discovered targets are much needed; natural sources have already provided the starting point for several successful anti-infectives, and many sources remain to be explored.

Key questions answered

• Which areas of drug development in infectious disease could have the greatest impact?
• How can the relatively new technology of proteomics be used to develop leads for drug development?
• How are proteomic techniques being used in the design and production of modern diagnostic tools for infectious diseases?
• How are genomic technologies changing the way lead compounds are generated and providing ideas for innovative targeted drugs?
• In which bacteria, viral, fungal and prion diseases are fundamental research efforts showing the most potential for identifying compounds suitable for drug development?

For more information, please contact :

http://www.aarkstore.com/reports/Innovations-in-Combating-Infectious-Diseases-Opportunities-in-therapeutics-and-diagnostics-through-application-of-proteomics-genomics-nanotechnology-and-novel-sources-of-lead-generation-47012.html

Tweet

The companies participating in the dental implant market have found [...]]]> Worldwide dental implants are poised to achieve significant growth as patients become aware of the health benefits achieved from having viable teeth. Dental implants are in the category of optional surgery and represent the type of consumer spending that is postponed in challenging economic environments.

The companies participating in the dental implant market have found ways to manage infection, providing a higher implant success rate. Implantable devices are more stable in the mouth, permitting fewer dental implant failures. 69% of adults ages 35 to 44 have lost at least one permanent tooth to an accident, gum disease, a failed root canal, or tooth decay. By age 74, 26% of adults have lost all of their permanent teeth. With the number of Americans over 55 growing by 60% in the next 20 years there is plenty of U.S. market opportunity. The baby boomer generation buying power exceeds $2 trillion in 2009.

The leading six dental implant manufacturers control of the market is based on the need for marketing in this segment, with Nobel Biocare holding the number one market position and Straumann holding a share of almost one-fifth and ranking as the firm number-two player. A large number of small manufacturers earlier accounting for a third of the market have shrunk to 14% of it.

Dental implant market innovations are those that position the vendor companies to meet aesthetic demands and increase clinician productivity. Positioning for profitable business patient care delivery can be challenging for clinicians. Tooth loss, gum and bone disease affect millions of people worldwide, on every continent, in every age group. Globally, several hundred million people are missing one or more teeth. More than 40 million people are fully edentulous in the Western developed world. These numbers are substantially higher in Asia, Africa and other parts of the world.

Worldwide, weaknesses in the global economy and sagging consumer confidence have led to an unprecedented slowdown in the dental market. Reduced income has kept many patients away from the dentist. People with steady incomes fear losing their jobs and are not spending even if they can afford to. Elective procedures are being postponed.

General practitioners are tending to treat patients in house with conventional alternative treatments, rather than referring them for implant treatment, despite its superiority. Customers are reducing stocks. Dental labs are more hesitant to invest in dental equipment, such as CAD/CAM scanners.

Dental implant market innovations are those that position the vendor companies to meet aesthetic demands and increase clinician productivity. Positioning for profitable business patient care delivery can be challenging for clinicians. Tooth loss, gum and bone disease affect millions of people worldwide, on every continent, in every age group. Globally, several hundred million people are missing one or more teeth. More than 40 million people are fully edentulous in the Western developed world. These numbers are substantially higher in Asia, Africa and other parts of the world.

For 2008 the global dental implant market was 2.3 billion Euros. The market for crowns and bridges is 3 billion Euros. These estimates size the opportunity of the global restorative and esthetic dentistry market. Nobel Biocare is the clear market leader in this market.

The outlook for 2009 is one of a demanding market environment. Deteriorating economic conditions in most markets continue to impact dental implant markets because consumers have less discretionary income. Visibility in economic recovery time remains low.

Nanotechnology Impacts The Dental Implant Market One of the most active and important current areas of research and application of nanotechnology is in the field of life sciences and healthcare. Many industry and business analysts now expect nanotechnology to revolutionize the pharmaceutical, medical devices, diagnostics and imaging sectors with annual markets of billions of pounds likely within five-ten years.

According to Susan Eustis, lead author of the study, “Nanotechnology has begun to impact the dental implant market in a dramatic manner. By increasing the complexity of the surface topography with the addition of nano-scale calcium phosphate (CAP) crystals new capabilities are available to clinicians. Surface topography plays a determinant role in the bone bonding phenomenon.”

Through a discrete crystalline deposition (DCD™) Process in which nano-scale crystals of calcium phosphate are added to the BioMet 3i OSSEOTITE® Dual Acid Etched Surface, a topographic complexity at the sub-micron scale is established. Changes in the surface improve healing and represent dramatic breakthroughs in technology.

Smaller market participants are active in their national markets and compete mainly on price, with limited investments in R&D, training, education, marketing and sales. In countries like Brazil, Russia and India these companies hold over 50% of the market. With the Internet evolving as a channel, larger participants gain market visibility and strategic advantage on return on investment for the dentist.

Expanding use of dental implants by dental surgeons and general practitioners indicates a growth market as soon as consumer confidence is stabilized.

Markets for dental implants at $3.4 billion in 2008 are anticipated to reach $8.1 billion by 2015, growing in response to demand for better teeth worldwide. The technology is achieving a maturity level that makes the implants last longer and work in a more reliable manner, stimulating demand from an aging population. This market is poised for rapid growth as soon as the global economy recovers. The technology is more mature, leading to implants that last longer.

Companies Profiled

Astra Tech
Dentsply
LVB / Biomet
Able Electropolishing
Denics International
Advantage Manufacturing Technologies
AstraZeneca Group
Autocam Medical
DOT GmbH
Implant Sciences
Nobel Biocare
Straumann
Zimmer
Mack Molding
OpenCell BioMed Inc. (OCBM)
Orchid Orthopedic Solutions
Orchid Keller
Raymor
Weldon School of Biomedical Engineering–Purdue
Westlake Plastics Company

Report Methodology
This is the 405th report in a series of market research reports that provide forecasts in communications, telecommunications, the internet, computer, software, and telephone equipment. The project leaders take direct responsibility for writing and preparing each report. They have significant experience preparing industry studies. Forecasts are based on primary research and proprietary data bases. Forecasts reflect analysis of the market trends in the segment and related segments. Unit and dollar shipments are analyzed through consideration of dollar volume of each market participation in the segment. Market share analysis includes conversations with key customers of products, industry segment leaders, marketing directors, distributors, leading market participants, and companies seeking to develop measurable market share. Over 200 in-depth interviews are conducted for each report with a broad range of key participants and opinion leaders in the market segment.

Table of Contents :
Dental Implant Executive Summary ES-1
Global Dental Implant Market ES-1
Nanotechnology Impacts The Dental Implant Market ES-3
Dental Implant Market Driving Forces ES-4
Innovation Drives Dental Implant Markets ES-9
Dental Implant Market Trends ES-9
Aging of the Population ES-11
Dental Implant Market Shares ES-11
Dental Implant Market Forecasts ES-13
Dental Implant Market Forecasts Reflect Uncertainty
In The Global Economy ES-15

1. Dental Implant Market Description and Market Dynamics 1-1
1.1 Dental Implant Definition 1-1
1.1.1 American Dental Association Recommended
Types Of Dental Implants 1-2
1.1.2 Dental Implant Longevity 1-2
1.1.3 Types of Dental Implants 1-4
1.1.4 Titanium Dental Implants 1-4
1.1.5 Root-Form Dental Implant 1-4
1.1.6 Ramus-Frame Dental Implant 1-5
1.1.7 Transosseous Dental Implant 1-5
1.1.8 Blade-Form Dental Implant 1-6
1.1.9 Types of Dental Implant Devices 1-6
1.2 Dental Implants Require Follow-Up Treatment 1-8
1.2.1 Poor Oral Health And Tooth Loss Associated
With Serious Health Problems 1-9
1.2.2 Dental Implant Target Markets 1-10
1.3 Dental Implants 1-10
1.3.1 Small-Diameter Dental Implants
Increasingly Popular In the US 1-11
1.3.2 Clinical Research on Osseo-integrated Dental Implants 1-11
1.3.3 Osseo-Integrated Dental Implants Placed In Bone 1-12
1.3.4 Success Of Implants Attributed To Osseo-Integration 1-12
1.3.5 Implant Failure Higher In Smokers 1-13
1.3.6 Proactive, Integrated, And Patient Centric Solutions 1-13

2. Dental Implant Market Shares and Market Forecasts 2-1
2.1 Dental Implant Market Driving Forces 2-1
2.1.1 Innovation Drives Dental Implant Markets 2-5
2.1.2 Dental Implant Market Trends 2-5
2.2 Aging of the Population 2-7
2.3 Dental Implant Market Shares 2-11
2.3.1 Nobel Biocare 2-14
2.3.2 Straumann 2-19
2.3.3 OpenCell BioMed (OCBM) 2-26
2.3.4 Zimmer 2-26
2.3.5 Zimmer Tapered Screw-Vent Implant 2-28
2.3.6 Astra Tech 2-28
2.3.7 Astra Tech Implant System 2-29
2.3.8 Biomet 3i NanoTite™ Surface 2-29
2.3.9 Dentsply 2-30
2.3.10 Dentsply Frialit Plus Surface Implants –
Prevention Instead Of Intervention For Esthetics 2-31
2.4 Dental Implant Market Forecasts 2-32
2.4.1 Dental Implant Market Forecasts Reflect
Uncertainty In The Global Economy 2-33
2.4.2 Dental CAD/CAM Shipments 2-37
2.4.3 Dental Regenerative Materials Market Forecasts 2-39
2.4.4 Dental Implant, CAD/CAM, Regenerative
Dentistry Shipments, Forecasts 2-40
2.4.5 Digital Dentistry 2-45
2.4.6 Small Diameter Dental Implant Forecasts 2-46
2.5 Implant Porous Coatings 2-46
2.5.1 Orchid Orthopedic Solutions 2-46
2.6 Number of Root Canals 2-47
2.7 Dental Implant Return on Investment ROI Analysis 2-47
2.8 Dental Implant Regional Analysis 2-49
2.8.1 AstraTech in Japan 2-52
2.8.2 Dentsply Dental Implant Regional Positioning 2-53
2.8.3 Dentsply in the United States 2-54
2.8.4 Dentsply Europe 2-54
2.8.5 Dentsply All Other Regions 2-55
2.8.6 Nobel Biocare in Europe, Middle East and Africa 2-55
2.8.7 Nobel Biocare in North America 2-55
2.8.8 Nobel Biocare in Asia 2-55

3. Dental Implant Product Description 3-1
3.1 Nobel Biocare 3-1
3.1.1 Nobel Biocare NobelActive™ Dental Implant 3-4
3.1.2 Nobel Biocare NobelReplace™ Dental Prosthetic Flexibility 3-8
3.1.3 Nobel Biocare / ISI (Imaging Sciences International)
Treatment Planning Software Partnership 3-10
3.1.4 Nobel Biocare Digital Dentistry 3-10
3.1.5 Nobel Biocare Small Diameter Implants And
Orthodontic Mini Screws 3-24
3.1.6 Nobel Biocare Dental Implant Digital Dentistry 3-25
3.2 Straumman 3-26
3.3 Zimmer Dental Implants 3-37
3.3.1 Zimmer Tapered Screw-Vent Implant 3-38
3.3.2 Zimmer Tapered SwissPlus Implant 3-39
3.3.3 Zimmer AdVent implant 3-40
3.3.4 Zimmer Straight Screw-Vent Implant 3-40
3.3.5 Zimmer Fixture Mount/Transfer Packaging 3-40
3.3.6 Zimmer MTX® Selective Surface 3-40
3.3.7 Zimmer HA Selective Surface 3-41
3.3.8 Zimmer Self-Tapping Implants 3-41
3.3.9 Zimmer Snap® Delivery System 3-42
3.3.10 Zimmer MTX™ Surface 3-42
3.3.11 Zimmer MP-1® HA Surface 3-42
3.3.12 Zimmer Surface Options 3-45
3.3.13 Zimmer Histomorphometric Evaluations 3-47
3.4 Astra Tech 3-48
3.4.1 Astra Tech Implant System 3-48
3.4.2 Astra Tech Implant System Atlantis™ -
CAD/CAM Patient-Specific Abutments For All
Major Implant Systems 3-59
3.4.3 Astra Tech Implant System Cresco™ 3-59
3.4.4 Astra Tech 3D Visualization Of Patient Anatomy 3-61
3.4.5 Astra Tech Atlantis™ Patient-Specific Abutments 3-64
3.4.6 Astra Tech Nanotechnologies for
Life Sciences and Healthcare 3-65
3.4.7 Astra Tech Implant Performance Indicators 3-66
3.4.8 Astra Tech CAD/CAM Technology 3-66
3.4.9 Astra Tech Signs Dental Implant
Research Agreement with University of Zürich 3-67
3.5 Biomet 3i NanoTite™ Surface 3-68
3.5.1 Biomet Microtopography Of The OSSEOTITE® Implant 3-68
3.5.2 Biomet Nanotechnology-Based Bone Bonding 3-71
3.5.3 Biomet NanoTite™ Certain® PREVAIL® Implant 3-71
3.5.4 Biomet 3i Innovations 3-72
3.5.5 Biomet 3i NanoTite™ Surface at 50,000X 3-72
3.5.6 Biomet NanoTite™ Tapered Prevail® Implant 3-73
3.5.7 Biomet Navigator™ System For CT Guided Surgery 3-73
3.5.8 Biomet Nano-Scale Calcium Phosphate (CaP) Crystals
Surface Complexity At The Sub-Micron Scale 3-73
3.5.9 Biomet 3i Navigator™ System -Instrumentation For
CT Guided Surgery 3-74
3.5.10 Biomet Resorbable Collagen Membrane 3-75
3.5.11 Biomet Research on How Blood Clot Attaches To An Implant 3-78
3.5.12 Biomet Contact Osteogenesis Optimizes Bone Healing 3-79
3.5.13 Biomet Increased Bone/Implant Contact Human Histology 3-79
3.5.14 BioMet NanoTite Implant Advantages 3-80
3.5.15 Biomet 3i Innovations 3-85
3.6 Dentsply 3-87
3.6.1 Dentsply Frialit Plus Surface Implants –
Prevention Instead Of Intervention For Esthetics 3-91
3.6.2 Dentsply Frialit Plus Stepped Implant Macro-Design 3-93
3.6.3 Dentsply Frialit plus Stepped Implant Micro-Design 3-93
3.6.4 Dentsply XiVE® plus Implants & XiVE® TG
plus Implants & Prosthetics 3-96
3.6.5 Dentsply Implant Placement 3-96
3.6.6 Dentsply XiVE GraphicXiVE Plus 3-97
3.6.7 Dentsply XiVE TG Transgingival Plus 3-98
3.6.8 Dentsply Surface Design 3-100
3.6.9 Dentsply XiVE TG GraphicXiVE TG Bar
Coping Offers Versatility when Fabricating Bar Constructions 3-101
3.7 OpenCell BioMed (OCBM) 3-102
3.8 Coatings For Dental Implants 3-106
3.9 Spire 3-106
3.10 Orchid Orthopedic Solutions 3-106
3.11 Bicon Short Dental Implants 3-107

4. Dental Implant Technology 4-1
4.1 Surface Treatments for Medical Applications 4-1
4.1.1 Coating and Surface Treatment 4-1
4.1.2 Ion Implantation 4-2
4.1.3 Ion Beam Texturing 4-2
4.1.4 Radiopaque Coatings 4-2
4.1.5 Conductive Metal Coatings 4-2
4.2 Measuring The Thickness Of Polymer Films
On Medical Implants 4-3
4.2.1 Metal-On-Metal Implant Coating Advantages 4-3
4.3 Implant Surgery Biomedical Bacterial Infection 4-6
4.3.1 Late-Stage Infections Caused By Bacterial
Spores Circulating In The Vascular System 4-7
4.3.2 Thin Coatings Can Be Applied To Biomedical
Devices With The Aim Of Providing Resistance To
Bacterial Colonization 4-8
4.3.3 Silver Nanoparticle Based Antibiotic Approaches 4-9
4.3.4 Fabrication Of A Surface Layer Of Covalently
Immobilized Antibiotic Molecules 4-10
4.4 Medthin Coating Products 4-12
4.5 Astra Tech Follow-Up Research Summary Of The
Radiographic Data Showing An Average Bone Loss 4-15
4.6 Low Temperature Growth Of Thin Film Coatings For
The Surface Modification Of Dental Prostheses 4-17
4.7 Battery Technology for Dental Implants 4-24
4.7.1 Battery Chemistries Technology 4-25
4.8 Breath Analyzers Detect Disease 4-28
4.9 Improving Biomaterials For Medical Implant Applications 4-29
4.9.1 Bioactive Materials 4-30
4.9.2 Forming A Chemical Bond With Bone 4-31
4.9.3 Bioactivity Increased Through Surface Modification 4-32
4.9.4 Biofilms Multilayered Colonies Of Bacteria 4-32
4.9.5 Biofilm Formation 4-32
4.9.6 Biofilms As A Major Contributor To Chronic Wounds 4-34
4.9.7 Acute or Chronic Infection in Some Biomaterial Applications 4-35
4.9.8 Biomaterials Research 4-37

5. Dental Implant Company Profiles 5-1
5.1 Able Electropolishing 5-1
5.2 Advantage Manufacturing Technologies 5-1
5.3 AstraZeneca Group 5-1
5.3.1 AstraZeneca Revenue 5-3
5.3.2 AstraZeneca Group / Astra Tech 5-8
5.3.3 Astra Tech Revenue 5-9
5.3.4 Astra Tech Acquires Atlantis Components 5-11
5.3.5 Astra Tech Digital Technology and
CAD/CAM Scientific Program 5-11
5.3.6 Astra Tech acquires Astra Tech AB an Innovative
Dental CAD/CAM company 5-12
5.3.7 Astra Tech Acquires Its Japanese Distributor,
Denics International 5-13
5.4 Autocam Medical 5-14
5.5 Dentsply 5-14
5.5.1 Dentsply Dental Specialty Products 5-16
5.5.2 Dentsply New Products: 5-17
5.5.3 Dentsply International Revenue 5-18
5.5.4 Dentsply International Product and
Customer Revenue Segments Information 5-19
5.5.5 Dentsply Market Segments 5-21
5.5.6 Dentsply Product Innovation 5-23
5.5.7 Dentsply United States 5-24
5.5.8 Dentsply Europe 5-24
5.5.9 Dentsply All Other Regions 5-24
5.6 DOT GmbH 5-25
5.7 Implant Sciences Corporation 5-25
5.8 LVB Acquisition / Biomet 5-27
5.8.1 Biomet acquired by Private Equity Consortium 5-29
5.9 Mack Molding Co. 5-29
5.10 Nobel Biocare 5-29
5.10.1 Nobel Biocare Revenue 5-30
5.10.2 Nobel Biocare acquires Alpha-Bio Tec and Medicim 5-33
5.10.3 Nobel Biocare Introduces Its New Implant NobelActive 5-33
5.10.4 Nobel Biocare CAD/CAM-Based Dentistry 5-34
5.10.5 Nobel Biocare Standardized Product Facilities 5-35
5.10.6 Nobel Biocare Regional Performance:
Increasingly Demanding Market Environment 5-35
5.10.7 Nobel Biocare Revenue By Region 5-38
5.10.8 Nobel Biocare Go-To-Market Approach 5-39
5.10.9 Nobel Biocare Strategic Positioning 5-40
5.11 OpenCell BioMed Inc. (OCBM) 5-42
5.12 Orchid Orthopedic Solutions 5-42
5.12.1 Orchid Keller 5-42
5.13 Raymor 5-44
5.14 Straumann 5-45
5.14.1 Straumann Market Share Gains in Europe and North America 5-47
5.14.2 Straumann Innovation Pipeline 5-49
5.14.3 Straumann Improves Efficiency And Market Share in 2008 5-51
5.14.4 Straumann Net Revenue 5-51
5.15 Weldon School of Biomedical Engineering–Purdue 5-52
5.16 Westlake Plastics Company 5-52
5.17 Zimmer 5-52
5.17.1 Zimmer Reports Fourth Quarter and 2008 Revenue 5-57
5.17.2 Zimmer Dental Implants 5-62
5.18 Selected Dental Implant Products and Companies 5-63

List of Tables and Figures
Table ES-1 ES-2
Dental Implant Market Innovations
Figure ES-2 ES-4
Biomet NanoTite™ Implant OSSEOTITE® Surface Images
Table ES-2 ES-6
Dental Implant Sustainable Market Growth Drivers
Table ES-2 (Continued) ES-7
Dental Implant Sustainable Market Growth Drivers
Table ES-3 ES-8
Dental Implant Market Driving Forces
Table ES-3 (Continued) ES-9
Dental Implant Market Driving Forces
Figure ES-4 ES-12
Worldwide Dental Implant Shipments Market Shares,
Dollars, 2008
Figure ES-5 ES-15
Worldwide Dental Implant Market Forecasts, Dollars,
2009-2015
Figure 1-1 1-3
Dental Implant Image
Table 1-2 1-6
Types of Dental Implant Devices
Table 1-3 1-7
Dental Implant Surface Treatment Methods
Table 1-4 1-7
Dental Restorations Using Implants
Table 1-5 1-8
Dental Implant Restoration Procedures
Table 1-6 1-10
Dental Implant Target Markets
Table 2-1 2-2
Dental Implant Sustainable Market Growth Drivers
Table 2-1 (Continued) 2-3
Dental Implant Sustainable Market Growth Drivers
Table 2-2 2-3
Dental Implant Market Driving Forces
Table 2-2 (Continued) 2-4
Dental Implant Market Driving Forces
Table 2-3 2-6
Vendor Positioning Strengths
Figure 2-4 2-8
Dental Implant Market Opportunity
Table 2-5 2-9
Clinicians, Surgeons Increasing Dental Implant Treatment Options
Figure 2-6 2-10
Worldwide Dental Implant Treatment Rate
Figure 2-7 2-12
Worldwide Dental Implant Shipments Market Shares, Dollars, 2008
Table 2-8 2-13
Worldwide Dental Implant
Shipments Market Shares, Dollars, 2008
Figure 2-9 2-15
NobelBiocare NobelActive Implants
Figure 2-10 2-16
Nobel BioCare Growth Drivers
Table 2-11 2-17
NobelBiocare Commercial Approach To Dental Implants
Table 2-11 (Continued) 2-18
NobelBiocare Commercial Approach To Dental Implants
Table 2-12 2-19
Straumann New-Generation Bone Level Implant Advances
Table 2-12 (continued) 2-20
Straumann New-Generation Bone Level Implant Advances
Figure 2-13 2-21
Straumann Dental Market Positioning
Figure 2-14 2-22
Straumann Dental Tooth Replacement By Indication
Table 2-15 2-25
Straumann Product Innovation
Figure 2-16 2-27
Zimmer Dental Implants
Figure 2-17 2-31
Dentsply Implant System Provides Lasting Implants
Figure 2-18 2-34
Worldwide Dental Implant Market Forecasts, Dollars,
2009-2015
Table 2-19 2-35
Worldwide Dental CAD/CAM Shipment Forecasts, Dollars,
2009-2015
Table 2-20 2-36
Worldwide Dental Implant Shipments, Forecasts,
Units and Dollars, 2009-2015
Table 2-21 2-38
Worldwide Dental CAD/CAM Shipments, Forecasts,
Dollars, 2009-2015
Figure 2-22 2-39
Worldwide Dental Regenerative Materials
Shipments, Dollars, 2009-2015
Table 2-23 2-40
Worldwide Dental Implant, CAD/CAM,
Regenerative Dentistry Shipments, Forecasts, Dollars, 2009-2015
Figure 2-24 2-41
Worldwide Dental Implant, CAD/CAM, Regenerative
Dentistry Shipments, Forecasts, Dollars, 2009-2015
Table 2-25 2-42
Noble Biocare New Technology Doubles Addressable Market
Figure 2-26 2-43
Fastest Growing Sectors in Dentistry
Figure 2-27 2-44
Dental Implant Market Penetration
Figure 2-28 2-48
NobelBiocare Platform for Dental Implant Sustainable Growth
Figure 2-29 2-49
NobelBiocare Platform for Dental Implant Sustainable Growth
Figure 2-30 2-50
Dental Implant Regional Market Segments, Dollars, 2008
Table 2-31 2-51
Regional Dental Implant Shipment Analysis
Market Shares, Dollars, 2008
Table 2-32 2-52
Dental Implant Regional Analysis Factors
Table 3-1 3-1
Nobel Biocare Dental Implant Solutions Indications
Figure 3-2 3-2
Nobel Biocare Dental Implant Solutions
Figure 3-3 3-3
Nobel Biocare Dental Implant Solutions
Table 3-4 3-5
Nobel Biocare NobelActive™ Dental Implant Features
Figure 3-5 3-6
Nobel Biocare NobelActive™ Dental Implant Features
Table 3-6 3-7
Nobel Biocare NobelActive™ Dental Prosthetic Flexibility
Table 3-7 3-8
Nobel Biocare NobelReplace™ Dental Prosthetic Flexibility
Table 3-8 3-9
Nobel Biocare NobelReplace™ Comprehensive Prosthetic Flexibility
Figure 3-9 3-11
Nobel Biocare Dental Implant Q2 2009 Solution Launches
Table 3-10 3-12
Nobel Biocare Dental Implant Digital Dentistry Aspects
Figure 3-11 3-13
Nobel Biocare Dental Implant Digital Dentistry
Table 3-12 3-14
Nobel Biocare Dental Implant Comprehensive Prosthetics
Table 3-13 3-15
Nobel Biocare Dental Individualized Prosthetics
Comprehensive Product Line
Table 3-13 (Continued) 3-16
Nobel Biocare Dental Individualized Prosthetics
Comprehensive Product Line
Table 3-13 (Continued) 3-17
Nobel Biocare Dental Individualized Prosthetics
Comprehensive Product
Line
Figure 3-14 3-18
Nobel Biocare Dental Implant Digital Dentistry
Figure 3-15 3-19
Nobel Biocare Nobel Procera Product Benefits
Figure 3-16 3-20
Nobel Biocare NobelProcera Scanner
Figure 3-17 3-21
Nobel Biocare Dental Implant Digital Dentistry
Figure 3-18 3-23
Nobel Biocare Dental Implant Digital Dentistry Software Features
Figure 3-19 3-24
Nobel Biocare Dental Implant Digital Dentistry Treatment Planning
Table 3-20 3-26
Straumann Product Innovation
Table 3-21 3-27
Straumann Flexibility and Ease of Use
Figure 3-22 3-28
Straumann Osseointegration And Secondary Stability Capabilities
Figure 3-23 3-29
Straumann Comprehensive Dental Implant Solutions
Figure 3-24 3-30
Straumann Comprehensive Dental Solutions
Figure 3-25 3-31
Straumann Comprehensive Product Portfolio
Figure 3-26 3-32
Straumann Regeneratives Capabilities
Figure 3-27 3-33
Straumann Dental Implant Capabilities
Figure 3-28 3-34
Straumann Dental Implant Regenerative Capabilities
Table 3-29 3-35
Straumann Roxolid Features
Table 3-30 3-36
Straumann Roxolid: Next Generation, High
Performance Material With Benefits
Figure 3-31 3-37
Zimmer Dental Implants
Figure 3-32 3-38
Zimmer Tapered Screw-Vent Implant
Figure 3-33 3-39
Single-stage Tapered SwissPlus implant
Figure 3-34 3-41
Zimmer Spline Twist
Table 3-35 3-43
Zimmer SwissPlus implant
Table 3-36 3-44
Zimmer Dental SwissPlus Single-Stage Implant System
Table 3-36 (Continued) 3-45
Zimmer Dental SwissPlus Single-Stage Implant System
Figure 3-37 3-46
Zimmer MTX Grit-Blast Machined Titanium Implant
Surface With Hydroxylapatite (HA) particles
Figure 3-38 3-48
Zimmer Implant
Table 3-39 3-50
Astra Tech Dental Implant System™
Table 3-39 3-51
Astra Tech Dental Implant System Surgical components
Table 3-39 (Continued) 3-52
Astra Tech Dental Implant System Restorative Components
Table 3-39 (Continued) 3-53
Astra Tech Dental Implant System Restorative Components
Table 3-39 (Continued) 3-54
Astra Tech Dental Implant System Restorative Components
Table 3-39 (Continued) 3-56
Astra Tech Dental Implant System Restorative Components
Table 3-39 (Continued) 3-57
Astra Tech Dental Implant System Restorative Components
Table 3-40 3-60
Astra Tech Implant System™
Table 3-41 3-61
Astra Tech Facilitates SimPlant™ Software From
Materialise Complete Planning System
Table 3-42 3-62
Astra Tech SimPlant™ Materialise Software Program
Table 3-43 3-63
Astra Tech BioManagement Communication Tool
Table 3-44 3-65
Astra Tech Positioning of Nanotechnologies for
Life Sciences and Healthcare
Table 3-45 3-69
Biomet Products
Table 3-45 (Continued) 3-70
Biomet Products
Table 3-46 3-71
Biomet Nanotechnology-Based Bone Bonding Implants–
Table 3-47 3-74
Biomet Nano-Scale Calcium Phosphate (CaP) Crystals
Figure 3-48 3-76
Biomet 3i NanoTite™ Surface Instruments and Materials
Figure 3-49 3-77
Biomet 3i NanoTite™ Surface at 50,000X
Table 3-50 3-80
Biomet NanoTite Implants
Figure 3-51 3-82
Biomet NanoTite™ Implant OSSEOTITE® Surface Images
Figure 3-52 3-83
Biomet NanoTite™ Implant Surface Image
Table 3-53 3-84
Biomet 3i NanoTite Implant Benefits
Figure 3-54 3-85
Biomet 3i Innovations
Figure 3-55 3-87
Dentsply Ankylos Dental Implant System
Figure 3-56 3-88
Dentsply Ankylos Dental Implant System Load Design
Figure 3-57 3-89
Dentsply Ankylos Dental Implant Data System Design
Figure 3-58 3-90
Dentsply Ankylos Dental Implant Data
System Thread and Load Design
Figure 3-59 3-91
Dentsply Ankylos Dental Implant Abutment Diameter
Table 3-60 3-92
Dentsply Frialit Plus Surface Esthetics Aspects
Figure 3-61 3-94
Dentsply Frialit Plus Stepped Implant Surface Design
Figure 3-62 3-95
Dentsply Friadentz Plus Stepped Implant Surface Design
Table 3-63 3-96
Dentsply XiVE® Plus Implants
Table 3-64 3-99
Dentsply XiVE TG Implant Benefits
Figure 3-65 3-101
Dentsply Bar Coping
Table 3-66 3-102
Dentsply Prefabricated Components
Table 3-67 3-104
OpenCell BioMed Inc. (OCBM) CNRC Phase-2 Report Results
Table 3-67 (Continued) 3-105
OpenCell BioMed Inc. (OCBM) CNRC Phase-2 Report Results
Figure 4-1 4-12
Ion Bond Medthin Coating Products
Table 4-2 4-13
Dental Bone Grafting Materials
Table 4-3 4-14
Dental Bone Grafting Procedures
Table 4-4 4-15
Dental Bone Grafting Research and Development
Figure 4-5 4-18
Dental Implant Alternative Treatments
Figure 4-6 4-19
Straumann Efficiency Gain – CAD/CAM Prosthetics
Figure 4-7 4-20
Dental Implant Alternative Treatments
Figure 4-8 4-21
Dental Implant Alternative Treatments
Figure 4-9 4-22
Straumann Roxolid: Next Generation,
High Performance Material Benefits
Table 4-10 4-23
NobelBiocare NobelProcera Technology
Table 4-11 4-25
Battery Chemistries At The Forefront For Implantation Devices
Figure 4-12 4-33
Biofilm Formation
Figure 5-1 5-5
AstraZeneca Regional Sales Revenue
Table 5-2 5-8
Astrazeneca Regional Revenue
Table 5-3 5-17
Dentsply New Products:
Table 5-4 5-27
Biomet Target Markets
Table 5-5 5-28
Biomet Product Portfolio
Table 5-6 5-38
Nobel Biocare Revenue By Region in EUR Million
Table 5-7 5-41
Nobel Biocare Strategic Positioning
Figure 5-8 5-54
Zimmer Analysis of Revenue by Product Segment and Region
Figure 5-9 5-55
Zimmer Sales by Product Segment and Geographical Segment
Table 5-10 5-56
Zimmer Positioning 

 For More information please contact :

http://www.aarkstore.com/reports/Worldwide-Nanotechnology-Dental-Implant-Market-Shares-Strategies-and-Forecasts-2009-to-2015-13607.html

Tweet

Key features of this report

• •Provides an analysis of market data (revenues) of healthcare nanotechnology applications in North America, Europe, Asia [...]]]> This report covers different regional application markets, while evaluating them over the next five years. It provides information about the largest regional markets and factors influencing them, while defining the opportunities they present.

Key features of this report

• •Provides an analysis of market data (revenues) of healthcare nanotechnology applications in North America, Europe, Asia and Rest of World that includes Middle East, Africa, Russia, Latin America and Australia.
• Studies key market drivers and restraints for the main market and evaluation of respective sub segments with respect to market dynamics.
• Discusses drug delivery and formulations, biocompatible implants, regenerative medicine and wound care and diagnostics under the applications market along with related sub segments.

Scope of this report

• Understanding the existing and emerging applications of healthcare nanotechnology and their relative and forecast market sizes
• Understanding the product/technological developments on which the companies are focusing for their growth.
• Understanding the different nanotechnology based tools and their importance in the development of new products and applications

Key Market Issues

• Nanotechnology initiatives by developing countries are helping in the development of new products and applications.
• The delay in commercialization due to strict regulations and manufacturing difficulties is inhibiting product reach.
• Stability of nanoparticles inside the biological tissues is an important issue to be considered to reduce contamination by drugs.
• The development of biodegradable nanostructures will be a growth driver in future since they eliminate the issue of excretion.

Key findings from this report

• The healthcare nanotechnology market growth is largest in North America, at $4.75bn in 2009, followed by Europe at $3.65.
• The nanotechnology drug delivery market is expected to grow at a CAGR of 21.7% for the period 2009-14, to reach almost $16bn by 2014.
• Biocompatible implants and coatings and diagnostics comprise some of the major applications which are estimated to experience high growth between 2009 and 2014, 42% and 21.8% respectively.

Key questions answered

• What are the important healthcare nanotechnology markets and their growth over the period 2009-14?
• What are the major applications that have emerged in different areas such as drug formulations and delivery, biocompatible implants and coatings, regenerative medicines and wound care and diagnostics?
• In which areas are the companies focusing while forming strategic alliances with other industry players?

Table of Contents
Nanotechnology in Healthcare
Executive summary 16
Market overview 16
Healthcare nanotechnology market dynamics 16
Nanomaterials & nanotools for the healthcare market 17
Healthcare nanotechnology application market 18
Company profiles 19
Chapter 1 Market overview 22
Summary 22
Introduction 23
Market definition 23
Healthcare nanotechnology business processes 24
Healthcare nanotechnology applications 24
Healthcare nanotechnology application prospects 25
Opportunity matrix 26
Challenge matrix 28
Patent analysis 29
Chapter 2 Healthcare nanotechnology market dynamics 34
Summary 34
Introduction 35
Regional markets 36
North America 37
Europe 38
Asia 38
RoW 39
Competitive landscape 39
R&D activities by applications 41
New product launches 42
Collaborations & agreements 43
Market drivers 56
Nanotechnology research initiatives in developing nations 56
Innovations are increasing 56
Reduced toxicity 56
Market inhibitors 57
Delay in commercialization 57
Stability and other issues 57
Need for particle evaluation 57
Chapter 3 Nanomaterials & nanotools for the healthcare market 60
Summary 60
Introduction 61
Nanomaterials 61
Nanocapsules 61
Drivers 61
Inhibitors 62
Opportunities 62
Nanoporous materials 63
Drivers 63
Opportunities 63
Quantum dots 63
Drivers 64
Inhibitors 64
Opportunities 64
Nanotubes 65
Drivers 65
Nanowires 65
Drivers 66
Inhibitors 66
Opportunities 66
Dendrimers 67
Drivers 67
Opportunities 68
Monoclonal antibodies 68
Drivers 68
Inhibitors 69
Opportunities 69
Nanocomposites 69
Fullerenes 70
Nanofilms 70
Drivers 71
Inhibitors 71
Opportunities 71
Nanotools 72
Nanoarrays 72
Drivers 72
Inhibitors 73
Opportunities 73
Nanobiochip 74
Drivers 74
Opportunities 75
Nanolithography arrays 75
Drivers 75
Inhibitors 76
Opportunities 76
Computer-assisted drug discovery 77
Nanomass spectrometry 77
Drivers 77
Inhibitors 78
Opportunities 78
Congruent Force Intermolecular Test (nanotype) C-FIT 78
Chapter 4 Healthcare nanotechnology application market 82
Summary 82
Introduction 83
Drug formulation and delivery 83
Formulation 84
Drivers 85
Inhibitors 86
Opportunities 86
Fluorescently encoded microparticles 86
Nanoparticulate formulation/systems 88
Fluoropolymers as material platforms for drug therapy 88
DNA nanoparticle technology to produce DNA drugs 89
Drug profiling using smart materials 90
Supercritical fluids and water based nanomaterials 91
Dendrimer nanotechnology products 92
Potential healthcare nanotechnology drug formulation application 93
Drug delivery 93
Drivers 94
Inhibitors 95
Opportunities 95
Nanoencapsulation using nano-device platform 96
Smart materials for encapsulation 97
Antimicrobial nanoencapsulation 98
Nanoscale cochlear drug delivery 99
Drug delivery using nanoparticles 99
Nanocrystals for drug delivery 102
Drug delivery coatings 103
Nanopores 103
Nanocomposites 104
Nanotransponders 105
Potential applications of healthcare nanotechnology drug delivery 105
Biocompatible implants and coatings 106
Drivers 108
Nanofibers fight immune response 108
Improvement in biocompatibility 108
Optimized coatings 108
Improvement in dental implants 108
Inhibitors 108
Improvement of implant depends upon coatings 108
Possibility of mass poisoning 109
Opportunities 109
Improved brain implants 109
Improvement in process for better coatings 109
Helpful in orthopedic devices 109
Surface modification 109
Device coating 110
Drivers 112
Inhibitors 112
Opportunities 112
Sol-gel coatings 113
Biocompatible nanocoatings 113
Nanoscale plasma coating 113
Light-activated antimicrobials 113
Silver nanoparticles 114
Hydrophobic coatings 114
Multifunctional coatings 114
Anti-fouling nanocoatings 114
Passive hydroxyapatite coating 115
Other protective coatings 115
Implants 116
Drivers 116
Opportunities 117
Potential biocompatible implants applications 117
Life support devices using novel biocompatible polymers 117
Stimulation electrodes using nanotechnology 117
Noninvasive killing of cancer cells using localized heat 118
Artificial vascular grafts 118
Bone graft substitutes 118
Regenerative medicine and wound care 118
Regenerative medicine/tissue engineering 119
Drivers 120
Inhibitors 121
Opportunities 121
Potential applications of regenerative medicines 123
Wound care 124
Drivers 124
Opportunities 125
Nanosilver gels 125
Nanogold gels 125
Diagnostics 126
Drivers 127
Improved bioassays 127
Earlier diagnosis and effective monitoring 127
Opportunities 127
Treatment of ovarian cancer 127
Development of immunoassays 128
Quantum dots applications 128
Nanoemulsions in multimodal molecular imaging and targeted therapeutics 128
Nanoparticles for biochemical applications 129
Magnetic nanoparticles for medical diagnostic imaging 129
Encapsulation of radioactive nanoparticle 129
Genome sequencing 129
Nanobiosensors 130
Nanoarray biochips 130
Silicon-based chips/sensors for pH and pressure 130
Micro- and nano-replication for point-of-use analytical applications 131
Nanocells 131
Redox enzymes 131
Other potential diagnostics applications 132
Smart card diagnostics 132
Novel microfluidic technologies 132
Chapter 5 Company profiles 134
Summary 134
Abraxis BioScience, Inc. 135
Company overview 135
Products and services 135
Company strategy 136
Access Pharmaceuticals, Inc. 137
Company overview 137
Products and services 137
Company strategy 138
AstraZeneca 138
Company overview 138
Products and services 139
Company strategy 139
AMAG Pharmaceuticals, Inc. 139
Company overview 139
Products and services 140
Company strategy 140
Aphios Corp. 140
Company overview 141
Products and services 141
Company strategy 142
Asklepios Biopharmaceutical Inc. 142
Company overview 143
Products and services 143
Company strategy 143
Capsulution Nanoscience AG 144
Company overview 144
Products and services 144
Company strategy 144
ConvaTec 145
Company overview 145
Products and services 145
Company strategy 146
Debiotech 146
Company overview 146
Products and services 146
Company strategy 147
Do-Coop Technologies Ltd. 147
Company overview 147
Products and services 147
Company strategy 148
Elan Corp. 148
Company overview 148
Products and services 148
Company strategy 149
Ferro Corp. 149
Company overview 149
Products and services 150
Company strategy 150
Flamel Technologies 150
Company overview 151
Products and services 151
Company strategy 151
GE Global Research 152
Company overview 152
Company strategy 152
GfE Medizintechnik GmbH 153
Company overview 153
Products and services 153
Company strategy 154
HemCon Medical Technologies, Inc. 154
Company overview 154
Company strategy 155
iCeutica Inc 155
Company overview 155
Products and services 156
Company strategy 156
Liquidia Technologies 157
Company overview 157
Company strategy 157
Luna Innovations Inc. 158
Company overview 158
Products and services 158
Company strategy 159
MagForce Nanotechnologies AG 159
Company overview 160
Products and services 160
Company strategy 161
Merck KGaA 161
Company overview 161
Products and services 162
Company strategy 162
MIV Therapeutics Inc 162
Company overview 163
Products and services 163
Company strategy 163
Nanomix 163
Company overview 164
Products and services 164
Company strategy 164
Nano Interface Technology, Inc 165
Company overview 165
Products and services 165
Company strategy 165
NanoCarrier Co., Ltd. 165
Company overview 166
Products and services 166
Company strategy 166
NanoDel Technologies 167
Company overview 167
Products and services 167
Company strategy 167
NanoHorizons Inc. 168
Company overview 168
Products and services 168
Company strategy 168
Nanoprobes, Inc. 169
Company overview 169
Products and services 169
Company strategy 169
Nanospectra Biosciences Inc. 170
Company overview 170
Products and services 170
Company strategy 170
Nanosphere, Inc. 171
Company overview 171
Products and services 171
Company strategy 172
Novartis AG 172
Company overview 173
Products and services 173
Company strategy 173
Pfizer 173
Company overview 173
Company strategy 174
PharmaSol GmbH 174
Company overview 174
Products and services 174
Company strategy 175
Pioneer Surgical Technology 175
Company overview 175
Products and services 175
Company strategy 176
pSivida 176
Company overview 176
Products and services 176
Company strategy 176
F. Hoffmann–La Roche Ltd. 177
Company overview 177
Products and services 177
Company strategy 177
Siemens Medical Solutions 178
Company overview 178
Products and services 179
Company strategy 179
Smith & Nephew 179
Company overview 179
Products and services 180
Company strategy 180
Starpharma Holdings Ltd. 181
Company overview 181
Products and services 181
Company strategy 182
T2 Biosystems Inc. 183
Company overview 183
Company strategy 183
Appendix 184
Patents 184
Glossary 218

List of Figures
Figure 1.1: Global healthcare nanotechnology market 23
Figure 1.2: Geographical patent share, 2003-08 30
Figure 1.3: Number of patents by region, 2003-09 30
Figure 1.4: Comparison of patent trends, 2004 vs 2009 31
Figure 2.5: Developmental strategies by major players, January 2007–November 2009 40
Figure 2.6: R&D activities by applications, Jan 2007–Nov 2009 41
Figure 2.7: New product launches, Jan 2007–Nov 2009 42
Figure 2.8: Collaborations & agreements by applications, Jan 2007–Nov2009 43
Figure 2.9: Relative importance of features of healthcare nanotechnology 58

List of Tables
Table 2.1: Global healthcare nanotech market, by geography ($m), 2007-14 37
Table 2.2: Mergers & acquisitions in healthcare nanotech market, 2007–09 44
Table 2.3: New product launches in healthcare nanotech market, 2007–09 45
Table 2.4: New product launches in healthcare nanotech market, 2007–09 (ctd) 46
Table 2.5: R&D in healthcare nanotech market, 2007–09 47
Table 2.6: R&D in healthcare nanotech market, 2007–09 (ctd 1) 48
Table 2.7: R&D in healthcare nanotech market, 2007–09 (ctd 2) 49
Table 2.8: R&D in healthcare nanotech market, 2007–09 (ctd 3) 50
Table 2.9: R&D in healthcare nanotech market, 2007–09 (ctd 4) 51
Table 2.10: R&D in healthcare nanotech market, 2007–09 (ctd 5) 52
Table 2.11: R&D in healthcare nanotech market, 2007–09 (ctd 6) 53
Table 2.12: Collaborations & agreements in healthcare nanotech market, 2007–09 54
Table 2.13: Collaborations & agreements in healthcare nanotech market, 2007–09 (ctd) 55
Table 4.14: Global healthcare nanotech drug formulation and delivery market, by product ($m), 2007–14 83
Table 4.15: Global healthcare nanotech drug formulation and delivery market, by geography ($m), 2007–14 84
Table 4.16: Global healthcare nanotechnology drug formulation market, by product ($m), 2007–14 85
Table 4.17: Global healthcare nanotech fluorescently encoded microparticles market, by geography ($m), 2007–14 87
Table 4.18: Global healthcare nanotech nanoparticulate formulation/systems market, by geography ($m), 2007–14 88
Table 4.19: Global healthcare nanotech fluoropolymers material platforms for drug therapy market, by geography ($m), 2007–14 89
Table 4.20: Global healthcare DNA nanoparticle technology to produce DNA drugs market, by geography ($m), 2007-14 90
Table 4.21: Global healthcare nanotech drug profiling using smart materials market, by geography ($m), 2007-14 91
Table 4.22: Global healthcare nanotech supercritical fluids and water based nanomaterials market, by geography ($m), 2007-14 91
Table 4.23: Global dendrimer nanotech products market by geography ($m), 2007-14 92
Table 4.24: Global healthcare nanotech drug delivery market by product ($m), 2007-14 94
Table 4.25: Global healthcare nanoencapsulation using nano-device platform market, by product ($m), 2007-14 96
Table 4.26: Global healthcare nanoencapsulation using nano-device platform market, by geography ($m), 2007-14 97
Table 4.27: Global market for smart materials encapsulating pharmaceuticals, by geography ($m), 2007-14 98
Table 4.28: Global healthcare nanotech antimicrobial nanoencapsulation, by geography ($m), 2007-14 98
Table 4.29: Global healthcare nanotech nanoscale cochlear drug delivery, by geography ($m), 2007-14 99
Table 4.30: Global healthcare nanotech drug delivery using nanoparticles market, by product ($m), 2007-14 100
Table 4.31: Global healthcare nanotech drug delivery using nanoparticles market, by geography ($m), 2007-14 100
Table 4.32: Global drug delivery using nanocrystals market, by geography ($m), 2007-14 102
Table 4.33: Global healthcare nanotech drug delivery coatings market, by geography ($m), 2007- 14 103
Table 4.34: Global healthcare nanopores market, by geography ($m), 2007-14 104
Table 4.35: Global healthcare nanocomposites market, by geography ($m), 2007-14 104
Table 4.36: Global healthcare nanotech nanotransponder market, by geography ($m), 2007-14 105
Table 4.37: Global healthcare nanotech biocompatible implants and coatings market, by products ($m), 2007-14 107
Table 4.38: Global healthcare nanotech biocompatible implants and coatings market, by geography ($m), 2007-14 107
Table 4.39: Global healthcare nanotech surface modification market, by geography ($m), 2007-14 110
Table 4.40: Global healthcare nanotech device coating market, by products ($m), 2007-14 111
Table 4.41: Global healthcare nanotech device coating market, by geography ($m), 2007-14 111
Table 4.42: Global healthcare nanotech implants market, by geography ($m), 2007-14 116
Table 4.43: Global healthcare nanotech regenerative medicine and wound care market, by products
($m), 2007-14 119
Table 4.44: Global healthcare nanotech regenerative medicine market, by product ($m), 2007-14 120
Table 4.45: Global healthcare nanotech wound care market, by products ($m), 2007-14 124
Table 4.46: Global healthcare nanotech diagnostics market, by products ($m), 2007-14 126
Table 4.47: Global healthcare nanotech diagnostics market, by geography ($m), 2007-14 127
Table 0.48: US patents 184
Table 0.49: US patents (ctd 1) 185
Table 0.50: US patents (ctd 2) 186
Table 0.51: US patents (ctd 3) 187
Table 0.52: US patents (ctd 4) 188
Table 0.53: US patents (ctd 5) 189
Table 0.54: US patents (ctd 6) 190
Table 0.55: US patents (ctd 7) 191
Table 0.56: US patents (ctd 192
Table 0.57: US patents (ctd 9) 193
Table 0.58: US patents (ctd 10) 194
Table 0.59: US patents (ctd 11) 195
Table 0.60: US patents (ctd 12) 196
Table 0.61: US patents (ctd 13) 197
Table 0.62: US patents (ctd 14) 198
Table 0.63: US patents (ctd 15) 199
Table 0.64: US patents (ctd 16) 200
Table 0.65: US patents (ctd 17) 201
Table 0.66: US patents (ctd 18) 202
Table 0.67: US patents (ctd 19) 203
Table 0.68: Europe patents 204
Table 0.69: Europe patents (ctd 1) 205
Table 0.70: Europe patents (ctd 2) 206
Table 0.71: Europe patents (ctd 3) 207
Table 0.72: Europe patents (ctd 4) 208
Table 0.73: Europe patents (ctd 5) 209
Table 0.74: Europe patents (ctd 6) 210
Table 0.75: Europe patents (ctd 7) 211
Table 0.76: Europe patents (ctd 212
Table 0.77: Europe patents (ctd 9) 213
Table 0.78: Europe patents (ctd 10) 214
Table 0.79: Europe patents (ctd 11) 215
Table 0.80: Japan patents 216
Table 0.81: Japan patents (ctd 1) 217
 
For More information please contact :

  
http://www.aarkstore.com/reports/Nanotechnology-in-Healthcare-Market-outlook-for-applications-tools-and-materials-and-40-company-profiles-38032.html 

Tweet

The mission of the two Italian clusters is to provide entrepreneurship opportunities, business support, commercialization of nanotechnology and polymer-based materials innovations and the creation of new companies in the Veneto and Campania regions. Since the first edition of [...]]]> Nanochallenge and Polymerchallenge is Veneto Nanotech and IMAST top initiative devoted to enterprise support.

The mission of the two Italian clusters is to provide entrepreneurship opportunities, business support, commercialization of nanotechnology and polymer-based materials innovations and the creation of new companies in the Veneto and Campania regions. Since the first edition of Nanochallenge in 2005, Veneto Nanotech and IMAST have assisted in the launch of more than 10 new technology businesses, providing them the early stage funding.

Unique among many international business plan competitions, Nanochallenge and Polymerchallenge 2010 has established strategic alliances with investors and large companies that support the initiative.
Their representatives attend the Final Contest to listen to the startup projects.

This year some of the partners of the competition include: Basf, Carel, Dainese, Eurotech, Fondazione Cassa di Risparmio di Padova e Rovigo, Gear-World, Italcementi, Lux Research, Sapio, PricewaterhouseCoopers, Veneto Sviluppo.

Teams with innovative business ideas in nanotechnology and polymer-based materials can register on line and submit the Executive Summary by 20 September 2010.A scientific jury selects the finalists that will compete in the Final Contest. An international jury selects the best projects that receive early stage funding and the strategic support to turn into a successful business from Veneto Nanotech and IMAST.

The final contest will be held at the University of Padova on November 25 and 26, 2010.

The final contest represents a unique opportunity of networking for winners and participants to the international business plan competition Nanochallenge and Polymerchallenge 2010 and it gathers researchers, scientists, investors, venture capitalists, business angels, entrepreneurs and R&D directors of large companies.

Tweet

Introduction

This Ovum study examines top business challenges, IT budget outlook, and spending priorities among pharmaceutical and biotechnology companies in the US, Canada, the UK, France, Germany, Japan, [...]]]> Aarkstore announce a new report  ” Business Trends: Pharmaceuticals Technology Understanding Your Life Sciences Customer 2009 (Customer Focus) ” through its vast collection of market research report.

Introduction

This Ovum study examines top business challenges, IT budget outlook, and spending priorities among pharmaceutical and biotechnology companies in the US, Canada, the UK, France, Germany, Japan, China and India. It is based on the results of Ovum’s Business Trends primary research, conducted in Q3 and Q4 2009, with a total of 150 life sciences companies.

Scope

*In-depth interviews with 150 pharmaceutical and biotechnology companies

*Geographic coverage includes: US, Canada, UK, France, Germany, Japan, China and India

*The study focuses on business challenges, IT budget outlook, and adoption rate of data and knowledge management solutions

*Respondents include IT decision-makers such as CIOs and CTOs

Highlights

For the life sciences industry, regulatory compliance is and will always be at the heart of every IT investment strategy. Moving past this, executives are increasingly turning to IT to help optimize business processes. As the end of the recession nears, life sciences companies will focus on completing IT projects that were put on hold in 2009.

With the patent cliff on the horizon, life sciences companies must have robust product pipelines to maintain steady revenue streams. Small pharma and biotech companies are especially under great pressure to develop a successful drug as they are relying on funding primarily from investors, with little or no revenue coming in.

As generic competition increases, pharma companies aim to globalize their brand and increase their market share in the emerging markets. To increase their presence, there is increased M&A activity with local organizations. In addition, pharma companies are outsourcing key business processes as they cut costs and become leaner.

Reasons to Purchase

*Validate your market messaging and positioning in the life sciences industry

*Compare pharmaceutical and biotechnology IT purchasing plans across geographies

*Identify emerging areas of concern for pharmaceutical and biotechnology companies

For more information, please visit :
http://www.aarkstore.com/reports/Business-Trends-Pharmaceuticals-Technology-Understanding-Your-Life-Sciences-Customer-2009-Customer-Focus–34914.html
Or email us at press@aarkstore.com or call +919272852585

Special offer till 31th Dec 2009

Tweet